| Literature DB >> 10903336 |
B R Lawson1, G J Prud'homme, Y Chang, H A Gardner, J Kuan, D H Kono, A N Theofilopoulos.
Abstract
IFN-gamma, a pleiotropic cytokine, is a key effector molecule in the pathogenesis of several autoimmune diseases, including lupus. Importantly, deletion of IFN-gamma or IFN-gammaR in several lupus-predisposed mouse strains resulted in significant disease reduction, suggesting the potential for therapeutic intervention. We evaluated whether intramuscular injections of plasmids with cDNA encoding IFN-gammaR/Fc can retard lupus development and progression in MRL-Fas(lpr) mice. Therapy significantly reduced serum levels of IFN-gamma, as well as disease manifestations (autoantibodies, lymphoid hyperplasia, glomerulonephritis, mortality), when treatment was initiated at the predisease stage, particularly when IFN-gammaR/Fc expression was enhanced by electroporation at the injection site. Remarkably, disease was arrested and even ameliorated when this treatment was initiated at an advanced stage. This therapy represents a rare example of disease reversal and makes application of this nonviral gene therapy in humans with lupus (and perhaps other autoimmune/inflammatory conditions) highly promising.Entities:
Mesh:
Substances:
Year: 2000 PMID: 10903336 PMCID: PMC314313 DOI: 10.1172/JCI10167
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808